Melatonin Scalp Solutions for Thinning Hair: What the Trials Measured

Before using a melatonin hair serum, check what its cited study counted. Hairs in their growing phase, hairs released by a pull test and visible scalp coverage are different outcomes. A product claim can sound broader than the measurement behind it.

The scalp research also concerns particular liquid formulas. It does not give instructions to crush a sleep tablet into a hair product or to take melatonin pills for thinning hair.

The women’s trial found different results at the front and back

The 2004 pilot randomized 40 women with androgenetic or diffuse alopecia to 0.1% melatonin solution or placebo once daily for six months. Researchers used trichograms to assess the proportion of sampled hairs in the growing, or anagen, phase.¹

Among the 12 women with androgenetic alopecia, the significant placebo comparison concerned the back of the scalp: P=.012. Among the 28 with diffuse alopecia, it concerned the frontal scalp: P=.046. The other diagnosis-region comparisons were not significant.¹

The small, region-specific results cannot promise uniform regrowth across a widening part.

The abstract also reports increased plasma melatonin during treatment, although levels did not exceed the physiological nighttime peak. Scalp application therefore should not be described as necessarily staying on the scalp.¹

Why that trial did not settle the treatment question

The 2016 Cochrane² review of female pattern hair-loss treatments included the pilot but listed it among studies without usable data for the review’s prespecified outcomes. Its table states that those outcomes were not addressed.²

That is a question of what was measured. It does not mean the trial found nothing, or that its growing-phase result establishes a patient-visible benefit. A study can produce a positive laboratory or sampling measure while leaving a treatment decision unresolved.

For a serum purchase, ask whether the evidence shows better coverage, less shedding or a change in sampled hair cycles. Ask which finding came from women with your diagnosed condition.

The largest report tested a different, combined formula

A 2012 paper³ reported five studies performed on behalf of ASATONA AG, which developed a cosmetic solution containing 0.0033% melatonin, biotin and ginkgo biloba. That is a different concentration and ingredient combination from the pilot.³

Its largest study followed 1,891 people, including 990 women, for 90 days. Pull-test results and investigator ratings improved. However, it was open-label and had no placebo group. The participants’ starting measurements supplied the comparison.³

A large enrollment does not resolve the missing comparison or separate melatonin from the other ingredients. These results cannot identify how much improvement the ingredient itself caused.

Later scrutiny highlights the same design limits

A 2024 review, Clinical Studies Using Topical Melatonin, distinguished the women’s placebo-controlled pilot from later open-label reports. It emphasized small samples, missing untreated comparisons and extra ingredients that complicate attribution.⁴

The review also examined advanced delivery formulations tested in men. Comparing two melatonin-containing preparations can help study delivery, but leaves the ingredient’s benefit against no melatonin unresolved. Those male studies do not automatically answer the question for women with pattern thinning.⁴

The useful next study would compare a defined formula with an appropriate control, measure outcomes people notice and follow participants long enough to assess durability.

Keep safety findings attached to the formula tested

The 2012 report’s placebo-controlled absorption study³ involved eight healthy women over two weeks. It found no significant adverse effect on reaction time or cortical arousal with its low-concentration formula. That small, short experiment cannot establish long-term safety for every scalp product.³

NCCIH’s⁵ melatonin guidance explicitly concerns dietary supplements. It notes insufficient long-term safety information and limited pregnancy and breastfeeding research. Those statements do not supply a scalp-serum safety trial.⁵

Bring the ingredient list, concentration and any oral melatonin use to the clinician or pharmacist. Pregnancy, breastfeeding, medicines and a scalp reaction belong in that discussion before adding an experimental product.

Compare options after identifying the cause

The AAD⁶ advises a dermatologist’s assessment because other causes of hair loss can resemble female pattern thinning. It identifies topical minoxidil as an FDA-approved treatment for women and advises that assessing its effect can take six to 12 months of continuous use. It also advises avoiding minoxidil during pregnancy, when planning pregnancy and while breastfeeding.⁶

The melatonin studies above do not establish equivalent results to minoxidil. If you already have a treatment plan, discuss the serum’s proposed role and how you would measure a benefit before replacing part of that plan.

Record the product, start date, other treatment changes and comparable part photographs. Chapter 8, “The Widening Part,” in Hair, Everywhere uses the Hair Log to organize that history and compare options. Bring the log to the review so the discussion concerns your pattern of change, as well as the product’s claims.